Table 2.

eGFR change and adverse events reported in the studies

Authors (yr)Study ArmseGFR Change (ml/min per 1.73 m2)AESAEHypercalcemiaDiscontinuationESRDDeath
Agarwal et al.26 (2005)Paricalcitol mean 9.5 μg/wk−3.0 (−3.1 to −2.9)9/577/57N/AN/AN/AN/A
Placebo−2.5 (−2.6 to −2.4)2/612/61
Alborzi et al.27 (2008)Paricalcitol 1 μg/d−3.2 (−8.1 to −1.7)N/AN/AN/A1/8N/AN/A
Paricalcitol 2 μg/d+6.9 (−1.4 to +15.2)0/8
Placebo+5.3 (−3.1 to +13.7)1/8
Fishbane et al.30 (2009)Paricalcitol 1 μg/dNo change within or between groups7/312/311/313/31N/AN/A
Placebo(data N/A)9/302/300/302/30
de Zeeuw et al.29 (2010)Paricalcitol 1 μg/d−1.2 (−3.8 to 1.4)3/9313/931/9315/932/930/93
Paricalcitol 2 μg/d−7.6 (−10.1 to −5.1)8/9519/953/9526/954/953/95
Placebo−0.1 (−2.6 to 2.4)5/9312/931/9320/931/930/93
De Boer et al.32 (2013)Paricalcitol 2 μg/d−6.3 (−13.5 to 0.9)14/22N/A1/222/22N/AN/A
Placebo−0.2 (−6.2 to 5.9)11/220/220/22
Thadhani et al.33 (2012)Paricalcitol 2 μg/d−4.1 (−4.3 to −3.9)92/11517/11526/11527/1156/1150/115
Placebo−0.1 (−0.2 to 0.0)87/11211/1121/11221/1121/1120/112
Liu et al.31 (2012)Calcitriol 0.5 μg 2×/wk−3.2 (−8.1 to +1.7)7/261/260/264/26N/AN/A
No treatment+0.0 (−4.9 to +4.9)9/240/240/243/24
Krairittichai et al.28 (2012)Calcitriol 0.5 μg 2×/wkBaseline 37 (32–41)4/46N/A0/465/51N/AN/A
No treatmentEnd 36 (31–42)6/450/453/48
Baseline 38 (31–42)
End 37 (31–43)
  • AE, adverse events; SAE, serious adverse events; N/A, not available.